HealthTree recruits over 1,000 participants for study on impact of COVID-19 on MM

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A total of 1,066 patients have joined a HealthTree observational study on COVID-19 and multiple myeloma. All participating patients have filled out a HealthTree profile by contributing their de-identified health data and answered survey questions related to their outcomes during the COVID-19 pandemic.

The aim of the study is to help patients and physicians use real data to drive future medical decisions.

The study was first announced on April 16, 2020. The anonymous answers will be aggregated and analyzed by myeloma researchers to identify recommendations for patients navigating myeloma during the COVID-19 pandemic. Initial study results will be available in July, and more extensive results will be published in December.

Table of Contents

YOU MAY BE INTERESTED IN

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
“Bridge to Bahia” exhibit.Source: Sylvester Comprehensive Cancer CenterKaren Estrada, a survivor of acute myeloid leukemia, used visual art to communicate with her two boys while undergoing a bone marrow transplant at Sylvester Comprehensive Cancer Center. Because Estrada’s treatment required isolation, and her young children could not yet read and write, she sought out other creative vessels to foster closeness between them.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login